LFG
GPCR icon

Larson Financial Group’s Structure Therapeutics GPCR Stock Holding History

Larson Financial Group’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$322 Buy
6
+1
+20% +$44 ﹤0.01% 3560
2026
Q1 		$241 Hold
5
– – ﹤0.01% 3426
2025
Q4 		$348 Buy
5
+2
+67% +$82 ﹤0.01% 3188
2025
Q3 		$84 Buy
+3
New +$60 ﹤0.01% 3333
2025
Q2 		– Sell
-9
Closed -$156 – 3368
2025
Q1 		$156 Buy
+9
New +$220 ﹤0.01% 2838

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Larson Financial Group's GPCR Position: Q2 2026 in Review

Larson Financial Group increased its Structure Therapeutics (GPCR) stake by 20% in Q2 2026, buying an estimated $44 and bringing the position to 6 shares worth $322. The position accounts for ﹤0.01% of the portfolio, ranked #3560.

Larson Financial Group first reported a position in GPCR in Q1 2025 and has held it in 5 quarters since. The position peaked at $348 in Q4 2025. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Larson Financial Group held 6 shares of Structure Therapeutics worth $322 as of Q2 2026.
  • Larson Financial Group bought 1 Structure Therapeutics share in Q2 2026, an estimated $44.
  • Structure Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3560 holding.
  • Larson Financial Group first reported a position in Structure Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Larson Financial Group's Structure Therapeutics position peaked at $348 in Q4 2025.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.